Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production

Journal of the Neurological Sciences

Volumn 253, Issue 1-2, 2007, Pages 53-60

  Jung, Tae Woo ^a   Lee, Ji Young ^a   Shim, Wan Sub ^a   Kang, Eun Seok ^a   Kim, Soo Kyung ^a,b   Ahn, Chul Woo ^a   Lee, Hyun Chul ^a   Cha, Bong Soo ^a  

^a Yonsei University College of Medicine   (South Korea)

^b CHA University   (South Korea)

Author keywords

Bax; Bcl 2; MPP+; Parkison's disease; ROS; Rosiglitazone

Indexed keywords

CATALASE; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; SUPEROXIDE DISMUTASE;

ANTIOXIDANT ACTIVITY; APOPTOSIS; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DEGENERATIVE DISEASE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; HUMAN CELL; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION;

1-METHYL-4-PHENYLPYRIDINIUM; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL LINE, TUMOR; CYTOCHROMES C; HERBICIDES; HUMANS; HYPOGLYCEMIC AGENTS; MITOCHONDRIA; NEUROBLASTOMA; NEURONS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-BCL-2; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; THIAZOLIDINEDIONES;

EID: 33846610917     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jns.2006.11.020     Document Type: Article

References (34)

1. Mattson M.P. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Biol 1 (1990) 120-129
2. Singer T.P., and Ramsay R.R. Mechanism of the neurotoxicity of MPTP. An update. FEBS Lett 274 (1990) 1-8
3. Seaton T.A., Cooper J.M., and Schapria A.H. Free radical scavengers protect doparminergenic cell line from apoptosis induced by mitochondrial complex I toxins. Brain Res 777 (1997) 110-118
4. Blum D., Torch S., Lambeng N., Nissou M.F., Benabid A.L., Sadoul R., et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 65 (2001) 135-172
5. Yang J., Liu X., Bhalla K., Kim C.N., Ibrad A., and Cai J. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275 (1997) 1129-1132
6. Cropton M. Bax, Bid and the permeabilization of the mitochondrial outer membrane in apoptosis. Curr Opin Cell Biol 12 (2000) 414-419
7. Thornberry N.A., and Lazebnik Y. Caspase: enemies within. Science 281 (1998) 1312-1316
8. Lawrence J., Marnett J.N.R., and James D.W. Endogenous generation of reactive oxidants and electrophiles and their reactions with DNA and protein. J Clin Invest 111 (2003) 583-593
9. +) cytotoxicity. Biochem Biophys Res Commun 137 (1986) 303-309
10. + opens the mitochondrial permeability transition pore and releases cytochrome c in isolated mitochondria via an oxidative mechanism. Biochim Biophys Acta 1453 (1999) 49-62
11. Patel J., Weston W., and Hemyari P. Rosiglitazone (RSG) decreases insulin resistance (IR) and improves beta-cell function (BCF) in patients with type 2 diabetes mellitus. Program and abstracts: Endocrine Society 81st Annual Meeting Abstract vol. 470 (1999) 3-153
12. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 351 (2004) 1106-1118
13. Takata Y., Kitami Y., and Yang Z.H. Vascular inflammation is negatively autoregulated by interaction between CCAAT/enhancer-binding protein-delta and peroxisome proliferator-activated receptor-gamma. Circ Res 91 (2002) 427-433
14. Ruan H., Pownall H.J., and Lodish H.F. Troglitazone antagonizes tumor necrosis factor-alpha-induced reprogramming of adipocyte gene expression by inhibiting the transcriptional regulatory functions of NF-kappa B. J Biol Chem 278 (2003) 28181-28192
15. Chawla A., Barak Y., Nagy L., Liao D., Tontonoz P., and Evans R.M. PPAR-γ dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7 (2001) 48-52
16. Mohanty P., Aljada A., Ghanim H., Hofmeyer D., Tripathy D., Syed T., et al. Evidence for a potent anti-inflammatory effect of rosiglitazone. J Clin Endocrinol Metab 89 (2004) 2728-2735
17. van Wijk J.P., and Rabelink T.J. PPAR-gamma agonists: shifting attention from the belly to the heart?. Arterioscler Thromb Vasc Biol 24 (2004) 798-800
18. Choy J.C., Granville D.J., Hunt D.W., and McManus B.M. Endothelial cell apoptosis: biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol 33 (2001) 1673-1690
19. Decker T., and Lohmann-Matthes M.L. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods 115 (1988) 61-69
20. Beers Jr. R.F., and Sizer I.W. A spectrophotometric method for measuring the breakdown of hydrogen peroxide by catalase. J Biol Chem 195 (1952) 133-140
21. Lebel C.P., Ali S.F., Mckee M.S., and Bondy C. Organomeal-induced increases in oxygen radical species: the potential of 2,7-dichlorofluorescin diacetate as an index of neurotoxic damage. Toxicol Appl Pharmacol 104 (1990) 17-24
22. Kehrer J.P., and Smith C.V. Free radicals in biology: sources, reactivities, and roles in the etiology of human diseases (1994), Academic Press, San Diego 25-62
23. Pistrosch F., Passauer J., Fisher S., Fuecker K., Hanefeld M., and Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 27 (2004) 484-490
24. Garg R., Kumbkarni Y., Aljada A., Mohanty P., Ghanim H., Hamouda W., et al. Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilatation in obese subjects. Hypertension 36 (2000) 430-435
25. Cory S., and Adams J.M. The Bcl-2 family: regulators of cellular life-or-death switch. Nat Rev Cancer 2 (2002) 647-656
26. Nicholls D.G., and Budd S.L. Mitochondria and neuronal survival. Physiol Rev 80 (2000) 315-360
27. Kluck R.M., Martin S.J., Zhou J.S., Green D.R., and Newmeyer D.D. Cytochrome c activation of CPP32-like proteolysis plays a critical role in a Xenopus cell-free apoptosis system. EMBO J 16 (1996) 4639-4649
28. Hartmann A., Hunot S., Michel P.P., Mureil M.P., Vyas Faucheux S.B., Mouatt-Prigent A.A., et al. Caspase-3: a vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci U S A 97 (2000) 2875-2880
29. Mandel S., Grunblatt E., Riederer P., Levites Y., and Youdium M.B.H. Neuroprotective strategies in Parkinson's disease: an update on progress. CNS Drugs 17 (2003) 729-762
30. Hockenbery D., Nunez G., Milliman C., Schreiber R.D., and Korsmeyer S.J. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348 (1990) 334-336
31. Heneka M.T., Klockgether T., and Feinstein D.L. Peroxisome proliferators-activated receptor-gamma ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo. J Neurosci 20 (2000) 6862-6867
32. Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., and Hirsch E.C. Protective action of the peroxisome proliferators-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease. J Neurochem 82 (2002) 615-624
33. Rhon T.T., Wong S.M., Cotman C.W., and Cribbs D.H. 15-Deoxy-Ä12,14-prostaglandin J2, a specific ligand for peroxisome proliferator-activated receptor-a, induces neuronal apoptosis. Mol Neurosci 12 (2001) 839-843
34. Baatile J., Langbein W.E., Weaver F., Maloney C., and Jost M.B. Effect of exercise on perceived quality of life of individuals with Parkinson's disease. J Rehabil Res Dev 37 (2000) 529-534